- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06301906
Red Yeast Rice for Primary Prevention of Hypercholesterolemia
March 7, 2024 updated by: Chang Gung Memorial Hospital
Gut Microbiota and Bile Acids Mediate the Clinical Benefits of Red Yeast Rice for Primary Prevention of Hypercholesterolemia: A Pilot Observational Study
This two-year observational study will be conducted at the outpatient clinic of the Department of Traditional Chinese Medicine of Taoyuan Chang Gung Hospital from February 26, 2024 to December 31, 2025.
This study will enroll 35~55 year-old male patients who are expected to take LipoCol Forte Capsules for primary prevention of hypercholesterolemia.
The investigators will collect the TCM constitution questionnaires from patients before taking LipoCol Forte Capsules and every three months after taking the medicine.
At the same time, blood will be drawn to detect glycated hemoglobin, fasting blood sugar, insulin, lipids profile, liver and kidney function, creatine kinase, predictive parameters of atherosclerotic cardiovascular disease, and plasma bile acids, etc. Fecal samples will also be collected to analyze the intestinal microbiota and fecal bile acid composition.
This study will evaluate the efficacy, durability and safety of LipoCol Forte capsules in the primary prevention of hypercholesterolemia in patients with different constitutions, as well as whether it can reduce the risk of cardiovascular disease, and its influence on bile acid metabolism and intestinal microbiota.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yueh Hsiang Huang, PhD
- Phone Number: 886-975360240
- Email: igighuang@gmail.com
Study Locations
-
-
-
Taoyuan, Taiwan, 333
- Recruiting
- Taoyuan branch of Chang Gung Memorial Hospital
-
Contact:
- Yueh Hsiang Huang, PhD
- Phone Number: 886-975360240
- Email: igighuang@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The investigators will collect the TCM constitution questionnaires from patients before taking LipoCol Forte Capsules and every three months after taking the medicine.
At the same time, blood will be drawn to detect glycated hemoglobin, fasting blood sugar, insulin, lipids profile, liver and kidney function, creatine kinase, predictive parameters of atherosclerotic cardiovascular disease, and plasma bile acids, etc. Fecal samples will also be collected to analyze the intestinal microbiota and fecal bile acid composition.
Description
Inclusion Criteria:
- Aged 35~55 years old, LDL-C≥130mg/dl or patients with diabetes or chronic kidney disease with LDL-C ≥ 100mg/dl, expected to receive LipoCol Forte Capsule 600mg bid
Exclusion Criteria:
- Have received anti-hyperlipidemic drugs or red yeast rice treatment within the past month;
- Female;
- Have experienced rhabdomyolysis or abnormal liver function ALT >72 U/L due to taking red yeast rice;
- Bleeding diseases, such as abnormal platelets, abnormal coagulation factors, or gastrointestinal tract infection within one month
- Liver insufficiency ALT >72 U/L or renal insufficiency eGFR < 30 mL/min/1.73 m2;
- Have ever had coronary heart disease, myocardial infarction or cerebrovascular disease;
- Stressful situations, including hospitalization or surgery within the past or next month, and cancer still being treated;
- Uncontrolled hypertension (blood pressure ≥160/100 mmHg);
- Use antibiotics, probiotics or weight-loss drugs for more than 3 consecutive days within 3 months before inclusion in the study;
- Drug abuse or poor compliance;
- Use of traditional Chinese medicine in the past month
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group 1
|
LipoCol Forte Capsule 600mg bid for 12 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Low Density Lipoprotein-Cholesterol (LDL-C)
Time Frame: before treatment, and 3, 6, 9, 12 months after treatments
|
This study will evaluate the efficacy and durability of LipoCol Forte capsules in the primary prevention of hypercholesterolemia.
|
before treatment, and 3, 6, 9, 12 months after treatments
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
10-Year ASCVD Risk
Time Frame: before treatment, and 3, 6, 9, 12 months after treatments
|
use ASCVD risk estimator to calculate the 10-Year ASCVD Risk after LipoCol Forte capsules treatment
|
before treatment, and 3, 6, 9, 12 months after treatments
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 26, 2024
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
February 29, 2024
First Submitted That Met QC Criteria
March 7, 2024
First Posted (Actual)
March 8, 2024
Study Record Updates
Last Update Posted (Actual)
March 8, 2024
Last Update Submitted That Met QC Criteria
March 7, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202301060A3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineUnknownPrimary HypercholesterolemiaUnited States
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
Merck Sharp & Dohme LLCTerminated
-
Danone JapanCompletedHealthy | Mild HypercholesterolemiaJapan
Clinical Trials on LipoCol Forte Capsule 600mg bid
-
National Taiwan University HospitalNational Science Council, TaiwanCompleted
-
Shanghai Vinnerna Biosciences Co., Ltd.Withdrawn
-
Aclaris Therapeutics, Inc.Completed
-
Galmed Research and Development, Ltd.Enrolling by invitationHepatic ImpairmentUnited States
-
National Taiwan University HospitalNational Science Council, TaiwanCompleted
-
Immunomolecular Therapeutics, Inc.WCCT GlobalCompletedType1 DiabetesUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingInhibition of Autophagy Synergizes Anti-tumor EffectChina
-
LegoChem Biosciences, IncCompletedPulmonary TuberculosisKorea, Republic of
-
Columbia UniversityWithdrawn
-
Suzhou Zanrong Pharma LimitedRecruitingAdvanced Solid Tumors | HER2-positive Breast CancerChina